Compendium of Cancer Genome Aberrations

CNS5:Volunteer Assignments and Opportunities: Difference between revisions

← Older edit
VisualWikitext
No edit summary
m due date
 
(25 intermediate revisions by 5 users not shown)
Line 44: Line 44:
|6/25/2023
|6/25/2023
|
|
|PENDING
|COMPLETE
|
|
|Laveniya Satgunaseelan (LS)
|Laveniya Satgunaseelan (LS)
Line 52: Line 52:
|[[CNS5:Oligodendroglioma,_IDH-mutant_and_1p/19q-codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted]]
|[[CNS5:Oligodendroglioma,_IDH-mutant_and_1p/19q-codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted]]
|Disease
|Disease
|Riley Lochner (trainee), Shashi Shetty (mentor)
|Riley Lochner (trainee);
Shashi Shetty (mentor)
|6/7/2022
|6/7/2022
|
|
Line 63: Line 64:
|[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]]
|[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]]
|Disease
|Disease
|Meenakshi Mehrotra
|Jieying Wu
|
|11/18/2025
|
|01/15/2026
|PENDING
|PENDING
|
|
Line 110: Line 111:
|5/3/2024
|5/3/2024
|
|
|PENDING
|PENDING - email reminder 9/4/2025
|
|
|LS
|LS
Line 118: Line 119:
|[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]]
|[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]]
|Disease
|Disease
|Laveniya Satgunaseelan (Linda Cooley - previous version)
|Laveniya Satgunaseelan
|
|
|
|
|PENDING
|COMPLETE
|
|
|LS
|LS
Line 173: Line 174:
|[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]]
|[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]]
|Disease
|Disease
|Jeremy Pulvers
|Layla Zhu
|9/13/2022<br />
|<br />3/2/2026
|
|
|PENDING
|PENDING
Line 184: Line 185:
|[[CNS5:High-grade_astrocytoma_with_piloid_features|High-grade astrocytoma with piloid features]]
|[[CNS5:High-grade_astrocytoma_with_piloid_features|High-grade astrocytoma with piloid features]]
|Disease
|Disease
|Wahab Khan
|2/8/2026
|
|
|
|PENDING
|
|
|
|
|
|
Line 195: Line 196:
|[[CNS5:Pleomorphic_xanthoastrocytoma|Pleomorphic xanthoastrocytoma]]
|[[CNS5:Pleomorphic_xanthoastrocytoma|Pleomorphic xanthoastrocytoma]]
|Disease
|Disease
|Wahab Khan
|15/04/2025
|
|
|
|COMPLETE
|
|2/8/2026 (Feb 8)
|
|
|LS
|LS
|
|
Line 228: Line 229:
|[[CNS5:Astroblastoma,_MN1-altered|Astroblastoma, MN1-altered]]
|[[CNS5:Astroblastoma,_MN1-altered|Astroblastoma, MN1-altered]]
|Disease
|Disease
|Milana.Djonovic (trainee), Laveniya/Madina
|4/26/2026
|6/15/2026
|PENDING
|
|
|
|LS
|
|
|
|
|
|
|
|
Line 338: Line 339:
|[[CNS5:Diffuse_leptomeningeal_glioneuronal_tumour|Diffuse leptomeningeal glioneuronal tumour]]
|[[CNS5:Diffuse_leptomeningeal_glioneuronal_tumour|Diffuse leptomeningeal glioneuronal tumour]]
|Disease
|Disease
|Laveniya Satgunaseelan  
|Laveniya Satgunaseelan
|9/11/2024
|9/11/2024
|
|
|Pending
|COMPLETE
|
|8/7/2025
|
|LS
|
|LS
|Testing 9/2024 somatic template
|Used for testing 9/2024 somatic template
|-
|-
|[[CNS5:Multinodular_and_vacuolating_neuronal_tumour|Multinodular and vacuolating neuronal tumour]]
|[[CNS5:Multinodular_and_vacuolating_neuronal_tumour|Multinodular and vacuolating neuronal tumour]]
Line 415: Line 416:
|[[CNS5:Supratentorial_ependymoma|Supratentorial ependymoma]]
|[[CNS5:Supratentorial_ependymoma|Supratentorial ependymoma]]
|Disease
|Disease
|
|Laveniya Satgunaseelan
|
|2/4/2026
|
|30/6/2026
|
|PENDING
|
|
|
|
Line 426: Line 427:
|[[CNS5:Supratentorial_ependymoma,_ZFTA_fusion-positive_|Supratentorial ependymoma, ZFTA fusion-positive]]
|[[CNS5:Supratentorial_ependymoma,_ZFTA_fusion-positive_|Supratentorial ependymoma, ZFTA fusion-positive]]
|Disease
|Disease
|
|Laveniya Satgunaseelan
|
|2/4/2026
|
|30/6/2026
|
|PENDING
|
|
|
|
Line 437: Line 438:
|[[CNS5:Supratentorial_ependymoma,_YAP1_fusion-positive|Supratentorial ependymoma, YAP1 fusion-positive]]
|[[CNS5:Supratentorial_ependymoma,_YAP1_fusion-positive|Supratentorial ependymoma, YAP1 fusion-positive]]
|Disease
|Disease
|
|Laveniya Satgunaseelan
|
|2/4/2026
|
|30/6/2026
|
|PENDING
|
|
|
|
Line 611: Line 612:
|[[CNS5:Medulloblastoma,_WNT-activated|Medulloblastoma, WNT-activated]]
|[[CNS5:Medulloblastoma,_WNT-activated|Medulloblastoma, WNT-activated]]
|Disease
|Disease
|Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City
|Lisa Lansdon, PhD (LGG trainee just finished);
Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City
|9/20/21
|9/20/21
|
|
Line 633: Line 635:
|[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]]
|[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]]
|Disease
|Disease
|Hannah Wollenzien
|1/11/2026
|
|
|Pending
|
|
|
|MS
|
|
|
|
|
|
|
Line 797: Line 799:
|[[CNS5:Pineoblastoma|Pineoblastoma]]
|[[CNS5:Pineoblastoma|Pineoblastoma]]
|Disease
|Disease
|Fang Fang (trainee)+Katie Schieffer (mentor)
|11/19/2025
|6/15/2026
|Pending
|
|
|LS
|
|
|
|
|
|-
|
|[[CNS5:Papillary_tumour_of_the_pineal_region|Papillary tumour of the pineal region]]
|
|Disease
|
|
|-
|[[CNS5:Papillary_tumour_of_the_pineal_region|Papillary tumour of the pineal region]]
|Disease
|
|
|
|
Line 851: Line 853:
|[[CNS5:Schwannoma|Schwannoma]]
|[[CNS5:Schwannoma|Schwannoma]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Neurofibroma|Neurofibroma]]
|[[CNS5:Neurofibroma|Neurofibroma]]
|Disease
|Disease
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|
|-
|
|
|
|
|
|
|-
|[[CNS5:Perineurioma|Perineurioma]]
|[[CNS5:Perineurioma|Perineurioma]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Hybrid_nerve_sheath_tumours|Hybrid nerve sheath tumours]]
|[[CNS5:Hybrid_nerve_sheath_tumours|Hybrid nerve sheath tumours]]
|Disease
|Disease
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|
|-
|
|
|
|
|
|
|-
|[[CNS5:Malignant_melanotic_nerve_sheath_tumour|Malignant melanotic nerve sheath tumour]]
|[[CNS5:Malignant_melanotic_nerve_sheath_tumour|Malignant melanotic nerve sheath tumour]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 917: Line 919:
|[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]]
|[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]]
|Disease
|Disease
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|
|-
|
|
|
|
|
|
|-
|[[CNS5:Cauda_equina_neuroendocrine_tumour_(previously_paraganglioma)|Cauda equina neuroendocrine tumour (previously paraganglioma)]]
|[[CNS5:Cauda_equina_neuroendocrine_tumour_(previously_paraganglioma)|Cauda equina neuroendocrine tumour (previously paraganglioma)]]
|Disease
|Disease
Line 992: Line 994:
|[[CNS5:Solitary_fibrous_tumour|Solitary fibrous tumour]]
|[[CNS5:Solitary_fibrous_tumour|Solitary fibrous tumour]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,057: Line 1,059:
|-
|-
|[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]]
|[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]]
|Disease
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|[[CNS5:Primary_intracranial_sarcoma,_DICER1-mutant|Primary intracranial sarcoma, DICER1-mutant]]
|Disease
|Disease
|
|
Line 1,067: Line 1,080:
|
|
|-
|-
|[[CNS5:Primary_intracranial_sarcoma,_DICER1-mutant|Primary intracranial sarcoma, DICER1-mutant]]
|[[CNS5:Ewing_sarcoma|Ewing sarcoma]]
|Disease
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|[[CNS5:Mesenchymal_chondrosarcoma|Mesenchymal chondrosarcoma]]
|Disease
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|[[CNS5:Chondrosarcoma|Chondrosarcoma]]
|Disease
|Disease
|
|
Line 1,078: Line 1,113:
|
|
|-
|-
|[[CNS5:Ewing_sarcoma|Ewing sarcoma]]
|[[CNS5:Chordoma|Chordoma]]
|Disease
|Disease
|
|
Line 1,089: Line 1,124:
|
|
|-
|-
|[[CNS5:Mesenchymal_chondrosarcoma|Mesenchymal chondrosarcoma]]
|Disease
|
|
====CHAPTER 9 (MELANOCYTIC TUMOURS)====
|
----
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|-
|-
|[[CNS5:Chondrosarcoma|Chondrosarcoma]]
|[[CNS5:Diffuse_meningeal_melanocytic_neoplasms:_Melanocytosis_and_melanomatosis|Diffuse meningeal melanocytic neoplasms: Melanocytosis and melanomatosis]]
|Disease
|Disease
|
|
Line 1,111: Line 1,156:
|
|
|-
|-
|[[CNS5:Chordoma|Chordoma]]
|[[CNS5:Circumscribed_meningeal_melanocytic_neoplasms:_Melanocytoma_and_melanoma|Circumscribed meningeal melanocytic neoplasms: Melanocytoma and melanoma]]
|Disease
|Disease
|
|
Line 1,123: Line 1,168:
|-
|-
|
|
====CHAPTER 9 (MELANOCYTIC TUMOURS)====
====CHAPTER 10 (HAEMATOLYMPHOID TUMOURS INVOLVING THE CNS)====
|
|
----
----
Line 1,143: Line 1,188:
----
----
|-
|-
|[[CNS5:Diffuse_meningeal_melanocytic_neoplasms:_Melanocytosis_and_melanomatosis|Diffuse meningeal melanocytic neoplasms: Melanocytosis and melanomatosis]]
|[[CNS5:Primary_diffuse_large_B-cell_lymphoma_of_the_CNS|Primary diffuse large B-cell lymphoma of the CNS]]
|Disease
|Disease
|
|
Line 1,154: Line 1,199:
|
|
|-
|-
|[[CNS5:Circumscribed_meningeal_melanocytic_neoplasms:_Melanocytoma_and_melanoma|Circumscribed meningeal melanocytic neoplasms: Melanocytoma and melanoma]]
!'''Disease'''
|Disease
!'''Page Type'''
|
!'''<span style="color:#0070C0">Author'''
|
!'''Date Assigned to Author'''
|
!'''Target Completion Date'''
|
!'''Author Content (Pending or Complete)'''
|
!'''Date Completed by Author'''
|
!'''Associate Editor'''
|
!'''Date of Last Editor Review'''
|
!'''Notes'''
|-
|-
|[[CNS5:Immunodeficiency-associated_CNS_lymphomas|Immunodeficiency-associated CNS lymphomas]]
|Disease
|
|
====CHAPTER 10 (HAEMATOLYMPHOID TUMOURS INVOLVING THE CNS)====
|
----
|
|
----
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|-
|-
|[[CNS5:Primary_diffuse_large_B-cell_lymphoma_of_the_CNS|Primary diffuse large B-cell lymphoma of the CNS]]
|[[CNS5:Lymphomatoid_granulomatosis|Lymphomatoid granulomatosis]]
|Disease
|Disease
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|[[CNS5:Intravascular_large_B-cell_lymphoma|Intravascular large B-cell lymphoma]]
|Disease
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|[[CNS5:MALT_lymphoma_of_the_dura|MALT lymphoma of the dura]]
|Disease
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|[[CNS5:Other_low-grade_B-cell_lymphomas_of_the_CNS|Other low-grade B-cell lymphomas of the CNS]]
|Disease
|
|
|
|
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[CNS5:Immunodeficiency-associated_CNS_lymphomas|Immunodeficiency-associated CNS lymphomas]]
|Disease
|
|
|
|
Line 1,215: Line 1,264:
|
|
|
|
|-
|[[CNS5:Anaplastic_large_cell_lymphoma_(ALK+/ALK−)|Anaplastic large cell lymphoma (ALK+/ALK−)]]
|Disease
|Jennie Thurston
|7/2/2023
|
|
|PENDING
|
|
|MS
|
|
|2021 template added; Did not yet convert to CNS5 namespace. Should Jennie instead do the related two pages in HAEM5 of "[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]" and "[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]"?
|-
|-
|[[CNS5:Lymphomatoid_granulomatosis|Lymphomatoid granulomatosis]]
|[[CNS5:T-cell_and_NK/T-cell_lymphomas|T-cell and NK/T-cell lymphomas]]
|Disease
|Disease
|
|
Line 1,230: Line 1,287:
|
|
|-
|-
|[[CNS5:Intravascular_large_B-cell_lymphoma|Intravascular large B-cell lymphoma]]
|[[CNS5:Erdheim-Chester_disease|Erdheim-Chester disease]]
|Disease
|Disease
|
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:MALT_lymphoma_of_the_dura|MALT lymphoma of the dura]]
|[[CNS5:Rosai-Dorfman_disease|Rosai-Dorfman disease]]
|Disease
|Disease
|
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Other_low-grade_B-cell_lymphomas_of_the_CNS|Other low-grade B-cell lymphomas of the CNS]]
|[[CNS5:Juvenile_xanthogranuloma|Juvenile xanthogranuloma]]
|Disease
|Disease
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|
|
|
|
|
|
|
|-
|-
|[[CNS5:Anaplastic_large_cell_lymphoma_(ALK+/ALK−)|Anaplastic large cell lymphoma (ALK+/ALK−)]]
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]]
|Disease
|Disease
|Jennie Thurston
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|7/2/2023
|N/A
|
|N/A
|PENDING
|N/A
|N/A
|N/A
|N/A
|
|
|MS
|
|2021 template added; Did not yet convert to CNS5 namespace. Should Jennie instead do the related two pages in HAEM5 of "[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]" and "[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]"?
|-
|-
|[[CNS5:T-cell_and_NK/T-cell_lymphomas|T-cell and NK/T-cell lymphomas]]
|[[CNS5:Histiocytic_sarcoma|Histiocytic sarcoma]]
|Disease
|Disease
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|
|
====CHAPTER 11 (GERM CELL TUMOURS)====
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
----
|
----
|
----
|-
|-
|[[CNS5:Erdheim-Chester_disease|Erdheim-Chester disease]]
|[[CNS5:Germ_cell_tumours_of_the_CNS|Germ cell tumours of the CNS]]
|Disease
|Disease
|
|
Line 1,296: Line 1,385:
|
|
|-
|-
|[[CNS5:Rosai-Dorfman_disease|Rosai-Dorfman disease]]
|Disease
|
|
====CHAPTER 12 (TUMOURS OF THE SELLAR REGION====
|
----
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|-
|-
|[[CNS5:Juvenile_xanthogranuloma|Juvenile xanthogranuloma]]
|[[CNS5:Adamantinomatous_craniopharyngioma|Adamantinomatous craniopharyngioma]]
|Disease
|Disease
|
|
Line 1,318: Line 1,417:
|
|
|-
|-
!'''Disease'''
|[[CNS5:Papillary_craniopharyngioma|Papillary craniopharyngioma]]
!'''Page Type'''
|Disease
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]]
|Disease
|
|
|
|
Line 1,340: Line 1,428:
|
|
|-
|-
|[[CNS5:Histiocytic_sarcoma|Histiocytic sarcoma]]
|[[CNS5:Pituicytoma,_granular_cell_tumour_of_the_sellar_region,_and_spindle_cell_oncocytoma|Pituicytoma, granular cell tumour of the sellar region, and spindle cell oncocytoma]]
|Disease
|Disease
|
|
Line 1,351: Line 1,439:
|
|
|-
|-
|[[CNS5:Pituitary_adenoma_/_pituitary_neuroendocrine_tumour|Pituitary adenoma / pituitary neuroendocrine tumour]]
|Disease
|
|
====CHAPTER 11 (GERM CELL TUMOURS)====
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|-
|
|[[CNS5:Pituitary_blastoma|Pituitary blastoma]]
----
|Disease
|
----
|-
|[[CNS5:Germ_cell_tumours_of_the_CNS|Germ cell tumours of the CNS]]
|Disease
|
|
|
|
Line 1,382: Line 1,460:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|
|
====CHAPTER 12 (TUMOURS OF THE SELLAR REGION====
====CHAPTER 13 (METASTASES TO THE CNS)====
|
|
----
----
Line 1,404: Line 1,493:
----
----
|-
|-
|[[CNS5:Adamantinomatous_craniopharyngioma|Adamantinomatous craniopharyngioma]]
|[[CNS5:Metastases_to_the_brain_and_spinal_cord_parenchyma|Metastases to the brain and spinal cord parenchyma]]
|Disease
|Disease
|
|
Line 1,415: Line 1,504:
|
|
|-
|-
|[[CNS5:Papillary_craniopharyngioma|Papillary craniopharyngioma]]
|[[CNS5:Metastases_to_the_meninges|Metastases to the meninges]]
|Disease
|Disease
|
|
Line 1,426: Line 1,515:
|
|
|-
|-
|[[CNS5:Pituicytoma,_granular_cell_tumour_of_the_sellar_region,_and_spindle_cell_oncocytoma|Pituicytoma, granular cell tumour of the sellar region, and spindle cell oncocytoma]]
|Disease
|
|
====CHAPTER 14 (GENETIC TUMOUR SYNDROMES INVOLVING THE CNS)====
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
|-
----
|[[CNS5:Pituitary_adenoma_/_pituitary_neuroendocrine_tumour|Pituitary adenoma / pituitary neuroendocrine tumour]]
|Disease
|
|
|
|
|
|
|
|
----
|
|
----
|-
|-
|[[CNS5:Pituitary_blastoma|Pituitary blastoma]]
|[[CNS5:Neurofibromatosis_type_1|Neurofibromatosis type 1]]
|Disease
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]]
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|
|-
|
|[[CNS5:Schwannomatosis|Schwannomatosis]]
|
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|-
!'''Disease'''
|[[CNS5:Von_Hippel-Lindau_syndrome|Von Hippel-Lindau syndrome]]
!'''Page Type'''
|Disease
!'''<span style="color:#0070C0">Author'''
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
!'''Date Assigned to Author'''
|N/A
!'''Target Completion Date'''
|N/A
!'''Author Content (Pending or Complete)'''
|N/A
!'''Date Completed by Author'''
|N/A
!'''Associate Editor'''
|N/A
!'''Date of Last Editor Review'''
|N/A
!'''Notes'''
|
|-
|-
|[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]]
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
====CHAPTER 13 (METASTASES TO THE CNS)====
|-
|
|[[CNS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]]
----
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
----
|N/A
|
|N/A
----
|N/A
|
|N/A
----
|N/A
|
|N/A
----
|
----
|
----
|
----
|
|
----
|-
|-
|[[CNS5:Metastases_to_the_brain_and_spinal_cord_parenchyma|Metastases to the brain and spinal cord parenchyma]]
!'''Disease'''
|Disease
!'''Page Type'''
|
!'''<span style="color:#0070C0">Author'''
|
!'''Date Assigned to Author'''
|
!'''Target Completion Date'''
|
!'''Author Content (Pending or Complete)'''
|
!'''Date Completed by Author'''
|
!'''Associate Editor'''
|
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[CNS5:Cowden_syndrome|Cowden syndrome]]
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|-
|[[CNS5:Metastases_to_the_meninges|Metastases to the meninges]]
|[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]]
|Disease
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|
|-
|
|[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]]
|
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|-
|[[CNS5:Naevoid_basal_cell_carcinoma_syndrome|Naevoid basal cell carcinoma syndrome]]
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
====CHAPTER 14 (GENETIC TUMOUR SYNDROMES INVOLVING THE CNS)====
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|-
|-
|[[CNS5:Neurofibromatosis_type_1|Neurofibromatosis type 1]]
|[[CNS5:Rhabdoid_tumour_predisposition_syndrome|Rhabdoid tumour predisposition syndrome]]
|Disease
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 1,543: Line 1,666:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]]
|[[CNS5:Carney_complex|Carney complex]]
|Disease
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 1,554: Line 1,677:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:Schwannomatosis|Schwannomatosis]]
|[[CNS5:DICER1_syndrome|DICER1 syndrome]]
|Disease
|
|
|
|
|
|
|
|
|-
|[[CNS5:Von_Hippel-Lindau_syndrome|Von Hippel-Lindau syndrome]]
|Disease
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 1,576: Line 1,688:
|N/A
|N/A
|N/A
|N/A
|N/A
|-
|[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]]
|Disease
|
|
|
|
|
|
|
|
|
|-
|-
|[[CNS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]]
|[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]]
|Disease
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|[[CNS5:Melanoma-astrocytoma_syndrome|Melanoma-astrocytoma syndrome]]
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
Line 1,599: Line 1,710:
|N/A
|N/A
|N/A
|N/A
|
|-
|[[CNS5:Familial_retinoblastoma|Familial retinoblastoma]]
|Disease
|
|
|
|
|
|
|
|
|-
|-
!'''Disease'''
!'''Disease'''
Line 1,611: Line 1,734:
!'''Notes'''
!'''Notes'''
|-
|-
|[[CNS5:Cowden_syndrome|Cowden syndrome]]
|[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]]
|Disease
|Disease
|[[DIG5:Volunteer Assignments and Opportunities|See DIG5 volunteer sheet for authorship status]]
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
Line 1,621: Line 1,743:
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]]
|[[CNS5:Fanconi_anaemia|Fanconi anaemia]]
|Disease
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 1,631: Line 1,754:
|N/A
|N/A
|N/A
|N/A
|N/A
|-
|[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]]
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|-
|[[CNS5:Naevoid_basal_cell_carcinoma_syndrome|Naevoid basal cell carcinoma syndrome]]
|Disease
|
|
|
|
|
|
|
|
|
|-
|-
|[[CNS5:Rhabdoid_tumour_predisposition_syndrome|Rhabdoid tumour predisposition syndrome]]
|[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]]
|Disease
|
|
|
|
|
|
|
|
|-
|[[CNS5:Carney_complex|Carney complex]]
|Disease
|
|
|
|
|
|
|
|
|-
|[[CNS5:DICER1_syndrome|DICER1 syndrome]]
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|-
|[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]]
|Disease
|
|
|
|
|
|
|
|
|-
|[[CNS5:Melanoma-astrocytoma_syndrome|Melanoma-astrocytoma syndrome]]
|Disease
|
|
|
|
|
|
|
|
|-
|[[CNS5:Familial_retinoblastoma|Familial retinoblastoma]]
|Disease
|
|
|
|
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]]
|Disease
|
|
|
|
|
|
|
|
|-
|[[CNS5:Fanconi_anaemia|Fanconi anaemia]]
|Disease
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 1,752: Line 1,765:
|N/A
|N/A
|N/A
|N/A
|N/A
|-
|[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]]
|Disease
|
|
|
|
|
|
|
|
|
|-
|-
|}
|}
Retrieved from "https://content.ccga.io/index.php/CNS5:Volunteer_Assignments_and_Opportunities"